BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hsu WH, Hsiao PJ, Lin PC, Chen SC, Lee MY, Shin SJ. Effect of metformin on kidney function in patients with type 2 diabetes mellitus and moderate chronic kidney disease. Oncotarget 2018;9:5416-23. [PMID: 29435189 DOI: 10.18632/oncotarget.23387] [Cited by in Crossref: 21] [Cited by in F6Publishing: 23] [Article Influence: 4.2] [Reference Citation Analysis]
Number Citing Articles
1 Barbieri PA, Mari-Ribeiro IP, Lupepsa L, Gigliolli AAS, Paupitz BR, de Melo RF, de Souza Leite Mello EV, de Brito Portela-Castro AL, Borin-Carvalho LA. Metformin-induced alterations in gills of the freshwater fish Astyanax lacustris (Lütken, 1875) detected by histological and scanning electron microscopy. Ecotoxicology 2022. [PMID: 36042120 DOI: 10.1007/s10646-022-02580-0] [Reference Citation Analysis]
2 Le T, Kim J, Park S. A Co-Doped Carbon Dot/Silver Nanoparticle Nanocomposite-Based Fluorescence Sensor for Metformin Hydrochloride Detection. Nanomaterials 2022;12:1297. [DOI: 10.3390/nano12081297] [Reference Citation Analysis]
3 Alahmadi AA, Alahmadi BA, Wahman LF, El-Shitany NA. Chamomile flower extract ameliorates biochemical and histological kidney dysfunction associated with polycystic ovary syndrome. Saudi J Biol Sci 2021;28:6158-66. [PMID: 34764746 DOI: 10.1016/j.sjbs.2021.06.066] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
4 Wu CT, Tsai YT, Jung HK, Fu SL, Hsiung CA, Liu HY, Lai JN. Metformin and the Risk of Anemia of Advanced Chronic Kidney Disease in Patients With Type 2 Diabetes Mellitus. J Clin Pharmacol 2021. [PMID: 34510471 DOI: 10.1002/jcph.1965] [Reference Citation Analysis]
5 Zhou G, Cui J, Xie S, Wan H, Luo Y, Guo G. Vitexin, a fenugreek glycoside, ameliorated obesity-induced diabetic nephropathy via modulation of NF-κB/IkBα and AMPK/ACC pathways in mice. Biosci Biotechnol Biochem 2021;85:1183-93. [PMID: 33704405 DOI: 10.1093/bbb/zbab012] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
6 Posma RA, Venema LH, Huijink TM, Westerkamp AC, Wessels AMA, De Vries NJ, Doesburg F, Roggeveld J, Ottens PJ, Touw DJ, Nijsten MW, Leuvenink HGD. Increasing metformin concentrations and its excretion in both rat and porcine ex vivo normothermic kidney perfusion model. BMJ Open Diabetes Res Care 2020;8:e000816. [PMID: 32816871 DOI: 10.1136/bmjdrc-2019-000816] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
7 Orloff J, Min JY, Mushlin A, Flory J. Safety and effectiveness of metformin in patients with reduced renal function: A systematic review. Diabetes Obes Metab 2021;23:2035-47. [PMID: 34009711 DOI: 10.1111/dom.14440] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Koroglu-Aydın P, Bayrak BB, Bugan I, Karabulut-Bulan O, Yanardag R. Histological and biochemical investigation of the renoprotective effects of metformin in diabetic and prostate cancer model. Toxicol Mech Methods 2021;31:489-500. [PMID: 34039237 DOI: 10.1080/15376516.2021.1919810] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
9 Nellaiappan K, Kumari P, Khatri DK, Singh SB. Diabetic Complications: An Update on Pathobiology and Therapeutic Strategies. Curr Diabetes Rev 2021. [PMID: 33745424 DOI: 10.2174/1573399817666210309104203] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
10 Mbara KC, Mofo Mato PE, Driver C, Nzuza S, Mkhombo NT, Gcwensa SK, Mcobothi EN, Owira PM. Metformin turns 62 in pharmacotherapy: Emergence of non-glycaemic effects and potential novel therapeutic applications. Eur J Pharmacol 2021;898:173934. [PMID: 33609563 DOI: 10.1016/j.ejphar.2021.173934] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
11 Olaniyi KS, Badejogbin OC, Saliu SB, Olatunji LA. Rescue effect of sodium acetate in diabetes mellitus-associated testicular dysfunction is accompanied by PCSK9 modulation. Biochimie 2021;184:52-62. [PMID: 33581194 DOI: 10.1016/j.biochi.2021.02.004] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
12 Clegg LE, Jing Y, Penland RC, Boulton DW, Hernandez AF, Holman RR, Vora J. Cardiovascular and renal safety of metformin in patients with diabetes and moderate or severe chronic kidney disease: Observations from the EXSCEL and SAVOR‐TIMI 53 cardiovascular outcomes trials. Diabetes Obes Metab 2021;23:1101-10. [DOI: 10.1111/dom.14313] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Kitamura K, Hayashi K, Ito S, Hoshina Y, Sakai M, Yoshino K, Endo K, Fujitani S, Suzuki T. Effects of SGLT2 inhibitors on eGFR in type 2 diabetic patients-the role of antidiabetic and antihypertensive medications. Hypertens Res 2021;44:508-17. [PMID: 33311577 DOI: 10.1038/s41440-020-00590-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
14 Elnaem MH, Mansour NO, Nahas AF, Baraka MA, Elkalmi R, Cheema E. Renal Outcomes Associated with the Use of Non-Insulin Antidiabetic Pharmacotherapy: A Review of Current Evidence and Recommendations. Int J Gen Med 2020;13:1395-409. [PMID: 33324086 DOI: 10.2147/IJGM.S285191] [Cited by in Crossref: 1] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
15 Dziedzic A, Saluk-Bijak J, Miller E, Bijak M. Metformin as a Potential Agent in the Treatment of Multiple Sclerosis. Int J Mol Sci 2020;21:E5957. [PMID: 32825027 DOI: 10.3390/ijms21175957] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
16 Guo J, Zheng HJ, Zhang W, Lou W, Xia C, Han XT, Huang WJ, Zhang F, Wang Y, Liu WJ. Accelerated Kidney Aging in Diabetes Mellitus. Oxid Med Cell Longev 2020;2020:1234059. [PMID: 32774664 DOI: 10.1155/2020/1234059] [Cited by in Crossref: 12] [Cited by in F6Publishing: 20] [Article Influence: 6.0] [Reference Citation Analysis]
17 Nath M, Bhattacharjee K, Choudhury Y. Pleiotropic effects of anti-diabetic drugs: A comprehensive review. Eur J Pharmacol 2020;884:173349. [PMID: 32650008 DOI: 10.1016/j.ejphar.2020.173349] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
18 Li B, Zhou P, Xu K, Chen T, Jiao J, Wei H, Yang X, Xu W, Wan W, Xiao J. Metformin induces cell cycle arrest, apoptosis and autophagy through ROS/JNK signaling pathway in human osteosarcoma. Int J Biol Sci 2020;16:74-84. [PMID: 31892847 DOI: 10.7150/ijbs.33787] [Cited by in Crossref: 20] [Cited by in F6Publishing: 47] [Article Influence: 10.0] [Reference Citation Analysis]
19 Lee MC, Lee CH, Chang LY, Chang CH, Zhang JF, Lee MR, Wang JY, Chen SM. Association of Metformin Use With End-Stage Renal Disease in Patients With Type 2 Diabetes Mellitus: A Nationwide Cohort Study Under the Pay-for-Performance Program. J Clin Pharmacol 2019;59:1443-52. [PMID: 31163098 DOI: 10.1002/jcph.1452] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
20 Davazdahemami B, Delen D. The confounding role of common diabetes medications in developing acute renal failure: A data mining approach with emphasis on drug-drug interactions. Expert Systems with Applications 2019;123:168-77. [DOI: 10.1016/j.eswa.2019.01.006] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 2.7] [Reference Citation Analysis]
21 Allegretti AS, Zhang W, Zhou W, Thurber TK, Rigby SP, Bowman-Stroud C, Trescoli C, Serusclat P, Freeman MW, Halvorsen YC. Safety and Effectiveness of Bexagliflozin in Patients With Type 2 Diabetes Mellitus and Stage 3a/3b CKD. Am J Kidney Dis 2019;74:328-37. [PMID: 31101403 DOI: 10.1053/j.ajkd.2019.03.417] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
22 Corremans R, Vervaet BA, D'Haese PC, Neven E, Verhulst A. Metformin: A Candidate Drug for Renal Diseases. Int J Mol Sci 2018;20:E42. [PMID: 30583483 DOI: 10.3390/ijms20010042] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
23 Yaribeygi H, Atkin SL, Pirro M, Sahebkar A. A review of the anti-inflammatory properties of antidiabetic agents providing protective effects against vascular complications in diabetes. J Cell Physiol 2019;234:8286-94. [PMID: 30417367 DOI: 10.1002/jcp.27699] [Cited by in Crossref: 33] [Cited by in F6Publishing: 41] [Article Influence: 8.3] [Reference Citation Analysis]